PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 7, 2026JAMA Oncology6 citations

Genomic Therapy Matching in Rare and Refractory Cancers

View Full Paper
FLFrank P. LinSTSubotheni ThavaneswaranJGJohn P. Grady

Key Points

  • This research aims to evaluate the impact of matching therapies to genomic biomarkers on survival in patients with advanced solid tumors.
  • Cohort study design focusing on patients with advanced solid tumors
  • Assessment of genomic biomarkers for therapy matching
  • Evaluation of survival outcomes in correlation with clinical trial evidence
  • Improved survival was noted when genomic therapy was supported by prospective clinical trial evidence
  • Findings highlight the importance of an evidence-based framework for therapy prioritization

Abstract

In this cohort study of patients with advanced solid tumors, matching therapies to genomic biomarkers was associated with improved survival only when supported by prospective clinical trial evidence. These findings support using an evidence-based framework to prioritize genomically guided therapies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/69abc1645af8044f7a4e9fd2https://doi.org/10.1001/jamaoncol.2026.0127
Ask AI
Helpful
Bookmark
Share
View Full Paper